|
Eedback Registration Disclaimer levoleucovorin Levoleucovorin Pharmaceutical company: Spectrumwww.spectrumpharm.com Pharmacologic classification: folate analog Therapeutic classification: antidote Pregnancy risk category: C AVAILABLE FORMS Single-use vial: 50 mg INDICATIONS AND DOSAGES To diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists after high-dose methotrexate therapy in osteosarcoma-- Adults with methotrexate level 10 micromolar at 24 hours, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours after methotrexate administration: 7.5 mg I.V. every 6 hours for 60 hours (10 doses starting 24 hours after start of methotrexate). Adults with methotrexate level remaining about 0.2 micromolar at 72 hours and more than 0.05 micromolar at 96 hours after methotrexate administration: Continue 7.5 mg I.V. every 6 hours until methotrexate level is less than 0.05 micromolar. Adults with met
micromolar methotrexate Ng late pregnancy Vaginitis Vertigo Vision loss micromolar methotrexate, acute Vomiting (in GI) Vomiting (in PED) Vomiting during early pregnancy Wheezing view all symptoms In This Topic Methotrexate ALERT: U.S. Boxed Warning Medication Safety Issues Pronunciation U.S. Brand Names Index Terms Generic Available Canadian Brand Names Pharmacologic Category Pharmacologic Category Synonyms Use: Labeled Indications Use: Unlabeled Investigational Pregnancy Risk Factor Pregnancy Considerations Lactation Contraindications Warnings Precautions Adverse Reactions Drug Interactions Ethanol Nutrition Herb Interactions Storage Reconstitution Compatibility Mechanism of Action Pharmacodynamics Kinetics Dosage Dosage: Combination Regimens Administration: I.M. Administration: I.V. Administration: Other Monitoring Parameters Reference Range Dietary Considerations Patient Education Geriatric Considerations Additional Information Dental Health: Effects on Dental Treatment Dental Health: Vasoconstrictor Local Anesthetic Precautions micromolar methotrexate.
micromolar methotrexate L tissues is more dependent upon the duration of exposure to the drug rather than the peak level achieved. When a patient has delayed drug elimination due to compromised renal function micromolar methotrexate, a third space effusion micromolar methotrexate, or other causes micromolar methotrexate, methotrexate serum concentrations may remain elevated for prolonged periods. The potential for toxicity from high dose regimens or delayed excretion is reduced by the administration of leucovorin calcium during the final phase of methotrexate plasma elimination. Pharmacokinetic monitoring of methotrexate serum concentrations may help identify those patients at high risk for methotrexate toxicity and aid in proper adjustment of leucovorin dosing. Guidelines for monitoring serum methotrexate levels micromolar methotrexate, and for adjustment of leucovorin dosing to reduce the risk of methotrexate toxicity micromolar methotrexate, are provided below in DOSAGE AND ADMINISTRATION. Methotrexate has been detected in human breast milk. The highest breast milk to plasma concentration ratio reached was 0.08:1. Page last.
micromolar methotrexate administration of doses greater than 25 mg is not recommended. Leucovorin Rescue after HighDose Methotrexate Therapy: The recommendations for leucovorin rescue are based on a methotrexate dose of 1215 grams m2 administered by intravenous infusion over 4 hours (see methotrexate package insert for full prescribing information).3 Leucovorin rescue at a dose of 15 mg (approximately 10 mg m2) every 6 hours for 10 doses starts 24 hours after the beginning of the methotrexate infusion. In the presence of gastrointestinal toxicity micromolar methotrexate, nausea or vomiting micromolar methotrexate, leucovorin should be administered parenterally. Serum creatinine and methotrexate levels should be determined at least once daily. Leucovorin administration micromolar methotrexate, hydration micromolar methotrexate, and urinary alkalinization (pH of 7.0 or greater) should be continued until the methotrexate level is below 5 x 10-8 M (0.05 micromolar). The leucovorin dose should be adjusted or leucovorin rescue extended based on the following guidelines: GUIDELINES FOR LEUCOVORIN DOSAGE A.
micromolar methotrexate 
micromolar methotrexate | | | | | |
micromolar methotrexate
Gue and the active isomer of 5-formyl tetrahydrofolic acid. This drug “rescues normal cells” as it provides tetrahydrofolic acid directly to normal cells so that they can resume active cell division after having been stopped by methotrexate. Cells that divide frequently, such as those lining the intestines, need tetrahydrofolic acid to make DNA and RNA. Methotrexate is a folate antagonist which blocks the enzyme dihydrofolate reductase (DHFR) and prevents folic acid from being converted to tetrahydrofolic acid. High dose methotrexate is a lethal dose of chemotherapy and patients depend upon levoleucovorin or leucovorin to rescue the normal cells so that normal body cells can continue to divide. Metabolism Peak levels of total tetrahydrofolate are found 0.9 hours after drug administration, with a mean terminal half-life of 5.1 hours. Drug Administration A 50 mg vial of drug is aseptically reconstituted with 5.3 mL of 0.9% Sodium Chloride for Injection USP, yielding 10 mg mL.
|
